How ScanScor Selects Biotech Candidates

ScanScor is designed to identify biotech companies with the potential for meaningful price repricing — often 20% to 100%+ — when a clear thesis succeeds or fails.

On July 1st, 2025, we screened 640 biotech companies for early signals that often appear before major price movement. Ranking was our first step, narrowing the universe to the most promising ~20% (124 companies).

A Disciplined Screening Process

Each ScanScor flag represents a measurable change in fundamentals that may indicate an emerging catalyst. Companies are ranked by how many of these indicators they’ve triggered, allowing us to focus only on the most compelling candidates for deeper analysis and prediction.

Original predictions were published in advance and remain publicly visible via archive.org .

Screening Signal Snapshot

21,639

High R&D to Revenue Ratio

14,302

Cash Runway Risk

4,255

Revenue Growth Acceleration

3,685

Revenue Spike ≥20%

1,349

Net Income Breakout

20

Upcoming Clinical Trial
(Phase 2)

13

Upcoming Clinical Trial
(Phase 3)

0

New Predictions Today

13

New Predictions This Month

150

Total Predictions

Why We Exclude Very Large Biotech Companies

Large biotech companies often have multiple approved products, diversified pipelines, and constant news flow. While they may be excellent long-term investments, they are generally poor candidates for prediction-driven analysis.

  • Gradual, institutionally-anchored price movement
  • Diluted impact of individual news events
  • Valuations driven by existing revenue
  • Limited potential for rapid repricing

Why We Also Exclude Extremely Small Companies

ScanScor generally avoids biotech companies with market capitalizations below ~$6 million. While these stocks can appear attractive, they often exhibit structural risks that undermine reliable analysis.

  • Frequent and extreme dilution
  • Listing and survival risk
  • Thin liquidity and distorted price signals
  • Financing-driven outcomes rather than science-driven ones

The ScanScor “Sweet Spot”

ScanScor focuses on companies that fall between these extremes — large enough to be viable, yet small enough to reprice quickly.

  • Concentrated pipelines or dominant lead programs
  • Clear, thesis-defining catalysts
  • Limited narrative dilution
  • Potential for decisive repricing

A Focused System by Design

ScanScor is not designed to cover every stock. It is designed to identify the right stocks — where insight, timing, and disciplined analysis can matter most.

The Final Step: Human Confirmation

ScanScor uses multiple discovery methods to surface candidate tickers — but before any normal prediction is generated, we apply one final gate: a quick human review.

What we confirm

  • The company fits the ScanScor size range
  • It is not “too newsy” or over-explained by the market
  • The key catalyst has not already fired and failed
  • No major structural red flags dominate the story

Why this matters

Prediction quality is often decided before a prediction is ever run. This final review helps us avoid obvious mismatch cases (too large, too noisy, already repriced), so the engine stays focused on situations where a thesis can realistically drive 20% to 100%+ repricing.

Official Policy: ScanScor may rank thousands of data points automatically, but we only run normal predictions after a candidate passes this final confirmation step. This keeps the system disciplined, consistent, and aligned with our core mission: finding biotech setups capable of decisive repricing.

Scroll to Top